Trial reportPloS one2011
Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial.
Trial report in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Helminth therapy (worms) for induction of remission in inflammatory bowel disease.The Cochrane database of systematic reviews · 2014Pooled it
- Helminth therapy (worms) for allergic rhinitis.The Cochrane database of systematic reviews · 2012Pooled it
- A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.Journal of Crohn's & colitis · 2017Trial
- Trial
- Geohelminths: Use in the Treatment of Selected Human Diseases.Pathogens (Basel, Switzerland) · 2024Review
- Systemic Immune Modulation by Gastrointestinal Nematodes.Annual review of immunology · 2024Review
- Mitigation ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Article
- Immune System Investigation Using Parasitic Helminths.Annual review of immunology · 2021Review
- Mining Helminths for Novel Therapeutics.Trends in molecular medicine · 2021Review
- Infection withVaccines · 2020Article
- Safety of viable embryonated eggs of the whipwormEFSA journal. European Food Safety Authority · 2019Article
- Solid Organ Transplant and Parasitic Diseases: A Review of the Clinical Cases in the Last Two Decades.Pathogens (Basel, Switzerland) · 2018Review
- Preventive Trichuris suis ova (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression.Scientific reports · 2017Article
- Soil-Transmitted Helminths in Tropical Australia and Asia.Tropical medicine and infectious disease · 2017Review
- Nematodes and human therapeutic trials for inflammatory disease.Parasite immunology · 2017Review
- The whipworm (Trichuris suis) secretes prostaglandin E2 to suppress proinflammatory properties in human dendritic cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- A parasite-derived 68-mer peptide ameliorates autoimmune disease in murine models of Type 1 diabetes and multiple sclerosis.Scientific reports · 2016Article
- Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?PLoS pathogens · 2016Review
- Bacteria-induced egg hatching differs for Trichuris muris and Trichuris suis.Parasites & vectors · 2015Article
- Helminths and the microbiota: parts of the hygiene hypothesis.Parasite immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledSymptoms after human infection with the helminth Trichuris suis have not previously been described. Exposure to helminths has been suggested as immune therapy against allergy and autoimmune diseases. We randomized adults with allergic rhinitis to ingest a dose of 2500 T. suis eggs or placebo every 21 days for 168 days (total 8 doses) in a double-blind clinical trial. In a previous publication, we reported a lack of efficacy and a high prevalence of adverse gastrointestinal reactions. The aim of the present study was to present a detailed description of the adverse event data and post-hoc analyses of gastrointestinal reactions. Adverse events and severity (mild, moderate, severe) were recorded daily by subjects, classified by organ using MedDRA 10.0, and event rates compared between subjects on T. suis treatment vs. subjects on placebo. T. suis-specific serum IgG antibodies were measured by a fluoroenzymeimmunoassay (Phadia ApS). During 163 days complete follow-up, subjects ingesting T. suis eggs (N = 49) had a three to 19-fold higher rate of events (median duration, 2 days) with gastrointestinal reactions (moderate to severe flatulence, diarrhea, and upper abdominal pain) compared with placebo subjects (N = 47). The highest incidence of affected subjects was seen from the first few days and until day 42 (3(rd) dose): 63% vs. 29% for placebo; day 163: 76% vs. 49% for placebo. Seroprevalences increased concurrently in the T. suis group: Day 59, 50%; day 90, 91%; day 170, 93%. The combined duration of episodes with onset before day 42 was ≤ 14 days in 80% of affected subjects. Age, gender, total IgE, and recent intestinal symptoms at baseline did not predict gastrointestinal side effects. In conclusion, during the first 2 months, repeated ingestions of 2500 T. suis eggs caused frequent gastrointestinal reactions lasting up to 14 days, whereas 4 months further treatment mainly provoked a subclinical stimulation.
trial registrationUniversity hospital Medical Information Network trial registry Reg. no. R000001298, Trial ID UMIN000001070.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.